Angiotensin receptor blockers for chronic heart failure and acute myocardial infarction

Angiotensin receptor blockers for chronic heart failure and acute myocardial infarction - JJV McMurray. Heart 2001;86:97-103.

References for web version only

1. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE investigators. N Engl J Med 1992;327:669- 77.
2. The AIRE Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The acute infarction ramipril efficacy (AIRE) study investigators. Lancet 1993;342:821- 8.
3. Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995;333:1670- 6.
4. Flather MD, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-inhibitor myocardial infarction collaborative group. Lancet 2000;355:1575- 81.
5. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999;341:709- 17.
6. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study. N Engl J Med 1999;100:2312- 18.
7. Wolny A, Clozel JP, Rein J, et al. Functional and biochemical analysis of angiotensin II forming pathways in the human heart. Circulation Res 1997;80:219- 27.
8. Voors AA, Pinto YM, Buikema H, et al. Dual pathway for angiotensin II formation in human internal mammary arteries. Br J Pharmacol 1998;125:1028- 32.
9. Petrie MC, Padmanabhan N, McDonald JE, et al. Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease. J Am Coll Cardiol 2001;37:
10. Jones B, Jarvis P, Lewis JA, et al. Trials to assess equivalence: the importance of rigorous methods. BMJ 1996;313:36- 9.
11. Siegel JP. Equivalence and non-inferiority trials Am Heart J 2000;139:166- 70.
12. Berry C, Norrie J, McMurray J. Are Angiotensin II receptor blockers more efficacious than placebo in heart failure? Implications of ELITE-2. Am J Cardiol 2001;87:606- 7.
13. Gainer JV, Morrow JD, Loveland A, et al. Effect of bradykinin-receptor blockade on the response to angiotensin-converting enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 1998;339:1285�92.
14. Squire IB, O�Kane KP, Anderson N, et al. Bradykinin B(2) receptor antagonism attenuates blood pressure response to acute angiotensin-converting enzyme inhibition in normal men. Hypertension 2000;36:132- 6.
15. Davie AP, Dargie HJ, McMurray JJ. Role of bradykinin in the vasodilator effects of losartan and enalapril in patients with heart failure. Circulation 1999;100:268- 73.
16. Labinjoh C, Newby DE, Dawson P, et al. Fibrinolytic actions of intra-arterial angiotensin II and bradykinin in vivo in man.Cardiovasc Res 2000;47:707- 14.
17. Tonkon M, Awan N, Niazi, et al. A study of the efficacy and safety of irbesartan in combination with conventional therapy, including ACE inhibitors, in heart failure. Irbesartan heart failure group. Int J Clin Pract 2000;54:11- 4, 16- 8.
18. Jorde UP, Ennezat PV, Lisker J, et al. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure. Circulation 2000;101:844- 6.
19. Horton R. From star signs to trial guidelines. Lancet 2000;355:1033- 4.
20. Parker AB, Azevedo ER, Baird MG, et al. ARCTIC: assessment of haemodynamic response in patients with congestive heart failure to telmisartan: a multicentre dose-ranging study in Canada. Am Heart J 1999;138:843- 8.
21. Sharma D, Buyse M, Pitt B, et al. The losartan heart failure mortality meta-analysis study group. Meta-analysis of observed mortality data from all controlled, double-blind, multiple-dose studies of losartan in heart failure. Am J Cardiol 2000;85:187- 92.
22. Senni M, Tribouilloy CM, Rodeheffer RJ, et al. Congestive heart failure in the community � a study of all incident cases in Olmsted County, Minnesota in 1991. Circulation 1998;98:2282- 9.
23. Vasan RS, Larson MG, Benjamin EJ, et al. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction � prevalence and mortality in a population-based cohort. J Am Coll Cardiol 1999;33:1948- 55.
24. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. N Engl J Med 1986;314:1547- 52.
25. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303- 10.
26. Benedict CR, Weiner DH, Johnstone DE, et al. Comparative neurohormonal responses in patients with preserved and impaired left ventricular ejection fraction � Results of the studies of left ventricular dysfunction (SOLVD) Registry. J Am Col Cardiol 1993;212:A146- 53.
27. Mindlen F, Nordaby R, Ruiz M, et al. The HOPE (heart outcomes prevention evaluation) study: the design of a large, simple randomized trial of an angiotensin converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. Can J Cardiol 1996;12:127- 37.
28. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N Engl J Med 2000;342:145- 53.
29. Cleland JG, Tendera M, Adamus J, et al. Perindopril for elderly people with chronic heart failure: the PEP-CHF study. The PEP investigators. Eur J Heart Failure 1999;1:211- 7.